Koole, Michel http://orcid.org/0000-0001-5862-640X
Van Weehaeghe, Donatienne http://orcid.org/0000-0001-6646-106X
Serdons, Kim
Herbots, Marissa
Cawthorne, Christopher http://orcid.org/0000-0002-5975-0354
Celen, Sofie http://orcid.org/0000-0002-6742-7469
Schroeder, Frederick A.
Hooker, Jacob M. http://orcid.org/0000-0002-9394-7708
Bormans, Guy http://orcid.org/0000-0002-0335-7190
de Hoon, Jan
Kranz, Janice E. http://orcid.org/0000-0003-2629-5583
Van Laere, Koen http://orcid.org/0000-0001-5200-7245
Gilbert, Tonya M. http://orcid.org/0000-0002-9198-1419
Funding for this research was provided by:
Alzheimer's Drug Discovery Foundation (2013722)
Article History
Received: 13 March 2020
Accepted: 25 May 2020
First Online: 8 July 2020
Compliance with ethical standards
:
: The authors declare that they have no conflict of interest.
: All procedures performed in studies involving human participants were approved by the institutional ethics committee for research, and in accordance with the principles of the 1964 Declaration of Helsinki and its later amendments.
: Written informed consent was obtained from all individual participants prior to their inclusion in the study.
: T.M.G. is a current employee of Eikonizo Therapeutics, Inc. F.A.S. and J.E.K. are co-founders and current employees of Eikonizo Therapeutics, Inc. J.M.H. is a co-founder of Eikonizo Therapeutics, Inc., consults for Psy Therapeutics, Inc., and is an inventor on IP encompassing EKZ-001, which is licensed to Eikonizo Therapeutics, Inc. The remaining authors declare no disclosures.